亿帆医药：三季度美国销售提成收入为依据美国合作伙伴提供的第三季度净销售收入计提

Core Viewpoint - The company clarified that the sales commission from the U.S. market for the third quarter of 2025 will be based on the net sales revenue provided by its U.S. partner for that quarter [2]. Group 1 - The company, Yifan Pharmaceutical (002019.SZ), confirmed that its product Yilishu will officially start selling in the U.S. terminal market in the third quarter of 2025 [2]. - The sales commission reported for the third quarter of 2025 corresponds to the net sales revenue generated by the U.S. partner in that same quarter [2].